Viva Biotech Ltd. (follow as ”Viva Biotech” or “company”, stock code: 1873.HK) was listed on the HKEx on May 9th 2019, and JunHe acted as PRC legal counsel for the company.
Viva Biotech is a leading contract research organization (CRO) which provides contract research services based on structure and owns a series of world-leading techniques along with a pioneering business model. Viva’s services covered the full spectrum of our customers’ needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Compared to the traditional CFS model (Cash-for-Service) adopted by most CROs, Viva Biotech developed a pioneering business model which combines the EFS model (Equity-for-Service) with the traditional CFS model. Meanwhile, the Sino-US Trade War was heated during the delivery phase of the project, which increased the difficulty of delivery. The JunHe team collaborated thoroughly with other intermediaries to complete the delivery and the JunHe team’s consistent rigorous working style and professional attitude was highly recommended by the clients and all other intermediaries.
In early 2017, JunHe began providing legal services to Viva Biotech including offering practical and constructive domestic and offshore listing plans, designing and demonstrating the listing plan and deal structure. In 2018 Viva fixed the HK listing plan and JunHe completed due diligence on the company’s domestic interests and assisted in the compliance reform and consecutive communications with the administration. In July 2018 the listing application was delivered and in December 2018 Viva passed the listing hearing of the HKEx; on May 9th 2019 Viva and was successfully listed on the HKEx mainboard.
The leading partners for the project were Ms. Zhao, Jun, Mr. TAO, Xudong and Mr. SHI, Tiejun.